Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study
- 231 Downloads
The purpose of this study is to assess the efficacy of 153Sm-EDTMP (Quadramet®) in a clinical setting.
We have conducted a retrospective study of all consecutive patients (pts) treated with 153Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected: (i) pain assessment according to the 10-step visual analogue scale (VAS), (ii) sleep disturbance related to pain, (iii) dose of analgesic medication, and (iv) answer to the following closed question “Do you think you obtained a benefit from treatment?” Success of treatment was defined by the combination of these four parameters.
Three hundred seventy consecutive 153Sm-EDTMP treatments for painful bone metastases were given. Patients had the following primary tumors: breast carcinoma (153), prostate carcinoma (155), lung carcinoma (27), or other cancers (35). Fifty-eight percent of the patients had received previous external osseous radiotherapy. Ninety-seven percent of the patients were treated with concomitant analgesics and 61% were treated with diphosphonates. A clinical benefit was described in 55.0% of cases at D30. Treatment was more effective in cases of breast and prostate cancers compared with other types of primary cancers. Patients described a benefit at D30 in 62, 58, 6, and 38% of cases of breast, prostate, lung, and other cancers. The subjective efficacy was accompanied by a decrease in analgesic intake in 35.0% of cases.
153Sm-EDTMP therapy is an effective supportive treatment in patients who suffer from bone metastases, especially in patients with breast or prostate cancer.
KeywordsSamarium153 Bone metastases Pain palliative Radiometabolic therapy
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D (1997) A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33:1583–1591CrossRefPubMedGoogle Scholar
- 4.Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA (1998) Palliation of pain associated with metastatic bone cancer using samarium-153lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16:1574–1581CrossRefPubMedGoogle Scholar
- 5.Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ (1999) Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylenediaminetetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 26:2–7CrossRefPubMedGoogle Scholar
- 9.Montesano T, Giacomobono S, Acqualagna G, Colandrea M, Di Nicola A, Travascio L, Giancamerla M, D'Apollo R, Toteda M, Ugolini F, Filesi M, Ronga G (2009) Our experience on pain palliation of bone metastases with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study. Clin Ter 160:193–199PubMedGoogle Scholar
- 13.Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A (2009) Phase II trial of consolidation docetaxel and Samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27:2429–2435CrossRefPubMedGoogle Scholar
- 16.Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopft DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ (2013) Repetitively dosed docetaxel and 153Samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer 119:3186–3194CrossRefPubMedPubMedCentralGoogle Scholar